Key result
High expression of a vesicle transport protein signature (SPM10) was an independent positive prognostic factor for metastasis-free survival in soft tissue sarcomas (HR 0.479).
Why the study?
Soft tissue sarcomas are rare and diverse mesenchymal cancers with limited treatment options.
Cohort (n=321)
Yes
Hazard Ratio: 0.479 (95% CI 0.285–0.803)
p-value: p=0.005
Provides a hypothesis-generating molecular taxonomy for rare sarcomas; leaves open whether these.
Soft tissue sarcomas (STS) are rare and diverse mesenchymal cancers with limited treatment options. Here we undertake comprehensive proteomic profiling of tumour specimens from 321 STS patients representing 11 histological subtypes. Within leiomyosarcomas, we identify three proteomic subtypes with distinct myogenesis and immune features, anatomical site distribution and survival outcomes. Characterisation of undifferentiated pleomorphic sarcomas and dedifferentiated liposarcomas with low infiltrating CD3 + T-lymphocyte levels nominates the complement cascade as a candidate immunotherapeutic target. Comparative analysis of proteomic and transcriptomic profiles highlights the proteomic-specific features for optimal risk stratification in angiosarcomas. Finally, we define functional signatures termed Sarcoma Proteomic Modules which transcend histological subtype classification and show that a vesicle transport protein signature is an independent prognostic factor for distant metastasis. Our study highlights the utility of proteomics for identifying molecular subgroups with implications for risk stratification and therapy selection and provides a rich resource for future sarcoma research.
No takes yet. Share an insight, caveat, or question.
Burns et al. (2023) conducted a cohort in Soft tissue sarcomas (n=321). High expression of vesicle transport protein signature (SPM10) vs. Low expression of vesicle transport protein signature (SPM10) was evaluated on Metastasis-free survival (MFS) (HR 0.479, 95% CI 0.285-0.803, p=0.005). High expression of a vesicle transport protein signature (SPM10) was an independent positive prognostic factor for metastasis-free survival in soft tissue sarcomas (HR 0.479).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: